<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04238598</url>
  </required_header>
  <id_info>
    <org_study_id>2019IA-PRF</org_study_id>
    <nct_id>NCT04238598</nct_id>
  </id_info>
  <brief_title>Intra-articular Pulsed Radiofrequency Neuromodulation Versus Intra-articular Steroids for Painful Knee Osteoarthritis</brief_title>
  <official_title>Sham-controlled Randomized Trial of Intra-articular Pulsed Radiofrequency Neuromodulation Versus Intra-articular Steroids for Painful Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center For Interventional Pain and Spine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Center For Interventional Pain and Spine</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy of intra-articular pulsed radiofrequency to intra-articular steroids
      in patients with moderate-severe painful osteoarthritis of the knee.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients Adult patients with intractable knee pain for more than 6 months and radiographic
      evidence of grade II, III or IV knee osteoarthritis. Must not have had a knee injection or
      other interventional procedure for knee pain within the past 12 weeks. Must be on stable
      medications for the past 12 weeks and willing to keep medications stable for the first 12
      weeks of the study.

      Study Design Pilot study will enroll 30 patients randomized 1:1:1.

        1. Active control - intra-articular 4 milliliters 0.5% bupivacaine + 10mg dexamethasone +
           sham Pulsed Radiofrequency

        2. Placebo control - intra-articular 5 milliliters 0.9% saline + sham Pulsed Radiofrequency

        3. Treatment group - intra-articular 5 milliliters 0.5% bupivacaine + Pulsed Radiofrequency

      Methods Two 18-gauge radiofrequency needle with 10 millimeter active tip will be placed
      intra-articularly from an anterolateral and anteromedial approach to target the medial and
      lateral compartments. Once satisfactory fluoroscopic placement is noted, the Pulsed
      Radiofrequency or sham-Pulsed Radiofrequency treatment will be administered. Subsequently,
      the injectate will be administered. Dexamethasone is selected as the corticosteroid as it is
      colorless and will be indistinguishable from the saline used in the Intra-articular Pulsed
      Radiofrequency and placebo groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>test, active, control</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Visual Analogue Scale pain scores</measure>
    <time_frame>1-week, 1-, 3-, 6-, and 12-months</time_frame>
    <description>Evaluates the level of pain. Minimum=0 Maximum=10, Larger number indicates worse outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Patient-Reported Outcomes Measurement Information System-29 and Western Ontario and McMaster Universities Osteoarthritis (Index)</measure>
    <time_frame>1-week, 1-, 3-, 6-, and 12-months</time_frame>
    <description>Evaluates level of pain. For Patient-Reported Outcomes Measurement Information System-29, Minimum= 8 and Maximum=40. For Western Ontario and McMaster Universities Osteoarthritis (Index), Minimum=0 Maximum=20. Larger number indicates worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Analgesic use</measure>
    <time_frame>1-week, 1-, 3-, 6-, and 12-months</time_frame>
    <description>Evaluates number of medications, doses of medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Timed Up and Go Test</measure>
    <time_frame>1-week, 1-, 3-, 6-, and 12-months</time_frame>
    <description>Evaluates physical mobility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Progression to Surgery</measure>
    <time_frame>1-week, 1-, 3-, 6-, and 12-months</time_frame>
    <description>Evaluates effectiveness of treatment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intra-articular 4 milliliters 0.5% bupivacaine + 10mg dexamethasone + sham Pulsed Radiofrequency</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>intra-articular 5 milliliters 0.9% saline + sham Pulsed Radiofrequency</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intra-articular 5 milliliters 0.5% bupivacaine + Pulsed Radiofrequency</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulse Radiofrequency</intervention_name>
    <description>Two 20-gauge radiofrequency needle with 10mm active tip will be placed intra-articularly from an anterolateral and anteromedial approach to target the medial and lateral compartments. Once satisfactory fluoroscopic placement is noted, the Pulsed Radiofrequency treatment will be administered.</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard of Care Intra- Articular Injection</intervention_name>
    <description>Two 20-gauge radiofrequency needle with 10mm active tip will be placed intra-articularly from an anterolateral and anteromedial approach to target the medial and lateral compartments. Once satisfactory fluoroscopic placement is noted, the Intra-Articular treatment will be administered.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Placebo Intra-Articular Injection</intervention_name>
    <description>Two 20-gauge radiofrequency needle with 10mm active tip will be placed intra-articularly from an anterolateral and anteromedial approach to target the medial and lateral compartments. Once satisfactory fluoroscopic placement is noted, the Placebo Intra-Articular treatment will be administered.</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Capable of giving written informed consent

          -  Patients aged 18 years or older

          -  Patients with unilateral or bilateral knee pain for at least 3 months

          -  Radiographic evidence of knee osteoarthritis

          -  Appropriate candidate for steroid injection as determined by the investigator

        Exclusion Criteria:

          -  Chronic knee pain caused by infection, inflammation, tumors, and fractures

          -  A history of acute knee pain, previous knee surgery, connective tissue diseases,
             progressive neurologic disease or uncontrolled psychiatric disorders

          -  The administration of steroids or hyaluronic acids within the last three months

          -  Coagulation disorders

          -  Local infection at the site of intervention planned

          -  Active litigation related to this pain complaint
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael A Fishman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center For Interventional Pain and Spine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashley Scherer, MS</last_name>
    <phone>3027503099</phone>
    <email>ashleys@centerisp.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Center for Interventional Pain and Spine</name>
      <address>
        <city>Exton</city>
        <state>Pennsylvania</state>
        <zip>19341</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Scherer, MS</last_name>
      <phone>302-750-3099</phone>
      <email>ashleys@centerisp.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 25, 2019</study_first_submitted>
  <study_first_submitted_qc>January 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2020</study_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

